Canadian Association of Gastroenterology Clinical Practice Guidelines: the use of infliximab in Crohn's disease.

@article{Fedorak2004CanadianAO,
  title={Canadian Association of Gastroenterology Clinical Practice Guidelines: the use of infliximab in Crohn's disease.},
  author={Richard N Fedorak},
  journal={Canadian journal of gastroenterology = Journal canadien de gastroenterologie},
  year={2004},
  volume={15 6},
  pages={
          367-70
        }
}
  • R. Fedorak
  • Published 1 August 2004
  • Medicine
  • Canadian journal of gastroenterology = Journal canadien de gastroenterologie
These guidelines are presented as a follow-up to the original Canadian Association of Gastroenterology Clinical Practice Guidelines: The use of infliximab in Crohn's disease, published in the Canadian Journal of Gastroenterology (1). The original guidelines represented publications between 1998 and 2000. The current guidelines have been updated to reflect knowledge gained from two pivotal randomized clinical trails, with the use of infliximab in the maintenance of inflammatory Crohn's disease… 

Review and clinical perspectives for the use of infliximab in ulcerative colitis.

A review of the literature is followed by practical recommendations regarding infliximab that address the needs of clinicians and UC patients that provide a lack of evidence-based information.

Canadian Association of Gastroenterology Clinical Practice Guidelines: The use of tumour necrosis factor-alpha antagonist therapy in Crohn's disease.

Tumour necrosis factor-alpha antagonist therapy has become a cornerstone in the management of moderate-to-severe Crohn's disease refractory to conventional treatment algorithms and confidence in the safety of these drugs is increasing, provided that therapy is administered in a clinical setting in which potential complications can be readily recognized and treated.

Medical management of inflammatory bowel disease among Canadian gastroenterologists.

Most Canadian gastroenterologists exhibited similar practice patterns with respect to the use of infliximab for induction and maintenance therapy of IBD.

Clinical experience with infliximab for Crohn's disease: the first 100 patients in Edmonton, Alberta.

The patient group in the present study realized significant clinical benefit, with minimal adverse effects, following treatment with infliximab, and clinical response rates paralleled those previously described in placebo controlled trials and retrospective clinical practice reviews.

Appropriate infliximab infusion dosage and monitoring: results of a panel meeting of rheumatologists, dermatologists and gastroenterologists.

Routine measurement of vital signs during infusion is not valuable in detecting acute infusion reactions and should only be performed in case of an acute infusion reaction, as confirmed by literature on inflammatory bowel disease.

Infliximab: an updated review of its use in Crohn's disease and rheumatoid arthritis.

  • G. KeatingC. Perry
  • Medicine
    BioDrugs : clinical immunotherapeutics, biopharmaceuticals and gene therapy
  • 2002
Infliximab therapy was generally well tolerated in clinical trials with the most common adverse events including upper respiratory tract infection, headache, nausea, coughing, sinusitis and diarrhoea and may be associated with an increased risk of reactivation of tuberculosis in patients with latent disease.

Infliximab for the Treatment of Crohn ’ s Disease : A Systematic Review and Cost-Utility Analysis Technology Report

Unpublished efficacy and effectiveness data were sought from pharmaceutical companies involved in the production and distribution of infliximab and the websites of relevant international government agencies were searched.

Enteral nutrition in the management of Crohn's disease.

  • A. Griffiths
  • Medicine
    JPEN. Journal of parenteral and enteral nutrition
  • 2005
This workshop aims to examine possible mechanisms of action of enteral nutrition as primary therapy, and to make evidence-based recommendations concerning its use in the new era of biologic therapies, when mucosal healing has become a realistic goal.

Long-term response rates to infliximab therapy for Crohn's disease in an outpatient cohort.

Patients treated with infliximab therapy for luminal Crohn's disease in the authors' outpatient clinic achieved excellent induction and maintenance of response rates, confirming the real-life efficacy of maintenance inflixIMab established in clinical trials.

Variation in Care in Pediatric Crohn Disease

There is variation in diagnostic and therapeutic interventions in the management of pediatric Crohn disease, and gaps exist between recommended and actual care.

References

SHOWING 1-10 OF 56 REFERENCES

Clinical use of Infliximab in Crohn’s disease: the Edinburgh experience

Infliximab is an established treatment for steroid‐resistant and fistulating Crohn’s disease. Although efficacy has been shown in clinical trials, financial implications often limit its use and

Infliximab in treatment of Crohn's disease: the Milan experience.

  • S. ArdizzoneE. Colombo G. Bianchi porro
  • Medicine
    Digestive and liver disease : official journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver
  • 2002

Safety and Steroid-Sparing Experience Using Infliximab for Crohn's Disease at a Pediatric Inflammatory Bowel Disease Center

Infliximab is safe and effective for treating pediatric patients with CD and a steroid-sparing effect was demonstrated, which suggests utility in the treatment of refractory disease.

Clinical experience with infliximab for Crohn's disease: the first 100 patients in Edmonton, Alberta.

The patient group in the present study realized significant clinical benefit, with minimal adverse effects, following treatment with infliximab, and clinical response rates paralleled those previously described in placebo controlled trials and retrospective clinical practice reviews.

Use of Infliximab in the Treatment of Crohn's Disease in Children and Adolescents

  • J. Hyams
  • Medicine
    The Journal of pediatrics
  • 2000
Infliximab is associated with short-term clinical improvement in children and adolescents with severe Crohn's disease, and the rapid return of disease activity in some patients suggests that additional dosing strategies may be required.

Infliximab (REMICADE) Therapy in the Treatment of Pediatric Crohn's Disease

The results of this trial suggest that infliximab may be safe and effective as short-term therapy of medically refractory moderate to severe CD in a pediatric population.

Successful desensitization and therapeutic use of infliximab in adult and pediatric Crohn's disease patients with prior anaphylactic reaction.

Two CD patients with a history of anaphylactic/anaphylactoid reactions to retreatment with infliximab who subsequently underwent successful desensitization and therapeutic infusion using parenteral dose escalation in an intensive care unit setting are presented.

Infliximab in Crohn's disease: first anniversary clinical experience

Clinical experience with infliximab closely parallels the results of the controlled clinical trials, and includes steroid-sparing effects.

Infliximab Treatment for Crohn's Disease: One-Year Experience in a Dutch Academic Hospital

The clinical experience with infliximab for active luminal and fistulous CD showed that the administration is safe, effective, and has high steroid-sparing efficacy.

Infliximab for the treatment of Crohn's disease: review and indications for clinical use in Canada.

  • R. Panaccione
  • Medicine
    Canadian journal of gastroenterology = Journal canadien de gastroenterologie
  • 2001
Infliximab, a murine chimeric monoclonal antibody directed toward tumour necrosis factor-alpha, is a highly effective treatment of active Crohn's disease, and the only drug therapy shown to be effective for the treatment of fistulizing Crohn't disease.
...